Tony Coles, a founding investor and chief executive of the US neuroscience company Yumanity Therapeutics, has joined the board of directors of Crispr Therapeutics AG, the gene-based medicines company. Dr Coles was previously CEO of Onyx Pharmaceuticals (now Amgen Inc) and has also held senior positions at NPS Pharmaceuticals, Vertex Pharmaceuticals Inc, Bristol-Myers Squibb Company and Merck & Co Inc. In March Dr Coles was named to a working group which is preparing for President Barack Obama’s Precision Medicine Initiative.
Crispr Therapeutics announced the appointment on 11 December 2015.
Copyright 2015 Evernow Publishing Ltd